April 19th 2024
The primary endpoint of the study was clinical remission at week 52 with vedolizumab
Risankizumab Meets Primary Endpoint of Clinical Remission for Moderate to Severe Ulcerative Colitis
March 28th 2023The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.
Read More
FDA Approves First-in-Class Microbiota-Based Live Biotherapeutic for C. Difficile Infection
December 1st 2022Live-jslm (Rebyota; Ferring Pharmaceuticals) is indicated for the prevention of recurring Clostridioides difficile infection among patients 18 years of age and older after an antibiotic treatment.
Read More
Risankizumab Demonstrates Significant Improvements In Patients with Crohn Disease
January 11th 2021A significantly greater proportion of patients with Crohn disease achieved both primary endpoints with overall safety results generally consistent with the known safety profile of risankizumab.
Read More
Plethora of Clinical Trials Explore Gastric Cancer Treatments
Pharmacists can play an integral role in collaborating with physicians to manage patient therapy.
Read More
Survey Shows Adopting New Vancomycin Guidelines is Priority for Pharmacists Despite Pandemic
April 16th 2020A survey conducted between March 30 to April 6 by InsightRx found that implementing the new vancomycin guidelines into the pharmacy community is as important as the coronavirus disease 2019 (COVID-19) in the healthcare system.
Read More